TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02417818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plasma Therapy (PlasmaDerm)
Description: Plasma Therapy (PlasmaDerm)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plasma Therapy (PlasmaDerm)
Description: Plasma Therapy (PlasmaDerm)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plasma Therapy (PlasmaDerm)
Description: Plasma Therapy (PlasmaDerm)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Therapy (PlasmaDerm)
Description: Plasma Therapy (PlasmaDerm)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plasma Therapy (PlasmaDerm)
Description: Plasma Therapy (PlasmaDerm)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plasma Therapy (PlasmaDerm)
Description: Plasma Therapy (PlasmaDerm)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)
Description: Repetitive Plasma Therapy (Repetitive PlasmaDerm)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)
Description: Repetitive Plasma Therapy (Repetitive PlasmaDerm)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)
Description: Repetitive Plasma Therapy (Repetitive PlasmaDerm)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)
Description: Repetitive Plasma Therapy (Repetitive PlasmaDerm)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)
Description: Repetitive Plasma Therapy (Repetitive PlasmaDerm)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)
Description: Repetitive Plasma Therapy (Repetitive PlasmaDerm)
Study: NCT01420848

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy
Description: Auriculotherapy stimulates points to achieve better emotional balance, mental and physiological.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: They were evaluated at the baseline,twelve sessions and 15-day follow-up and received 12 sessions through the Fist and Outer ear points.
Study: NCT03951454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conexiones
Description: 5 Conexiones telephone sessions

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Taking Time
Description: 1 Taking Time telephone session
Study: NCT00790283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTCA with stent implantation
Description: Eligible patients will be randomly assigned to the implantation of one (or more) Numen or Vision/Mini Vision stent.~Each patient will undergo a 1-month follow-up and a clinical visit at 6 months from the procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTCA with stent implantation
Description: Eligible patients will be randomly assigned to the implantation of one (or more) Numen or Vision/Mini Vision stent.~Each patient will undergo a 1-month follow-up and a clinical visit at 6 months from the procedure.
Study: NCT01381796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NP101
Description: comparison of NP101 with minor patch modifications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101
Description: comparison of NP101 with minor patch modifications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101
Description: comparison of NP101 with minor patch modifications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sumatriptan succinate
Description: tablet, 100 mg
Study: NCT02365519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LME636 ophthalmic solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LME636 Vehicle
Description: Inactive ingredients used as a placebo comparator
Study: NCT02291679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Study: NCT04064879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AD-SVF
Description: Intravenous, intra-articular, and soft tissue injection delivery of SVF. Target regions include forehead, temporal, and suboccipital regions.
Study: NCT04292249

Intervention type: OTHER
Intervention: Blood sampling
Description: Analysis will be performed using commercially available analyses (suPARnostic® kit (validated to measure suPAR concentrations between 0.6 and 22 ng/mL) (ViroGates)). HsCRP will be measured by high sensitivity CRP assays (Tina-quant hs-CRP latex assay (validated to measure CRP concentrations between 0.3 - 20 mg/L) (Roche/Hitachi)). In patients with CRP\>20 mg/L a regular CRP-measurement will be performed.
Study: NCT03948191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99Tc-MDP(99Technetium-Methylenediphosphonate Injection)
Description: 15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.
Study: NCT02128464

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient specific cutting guides
Description: Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard knee cutting guides
Description: Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
Study: NCT01024426

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced health facility-based care
Description: The intervention is designed to address barriers to delivering quality care at health centers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
Study: NCT00788879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TSSC Randomized Behavioral Intervention for weight loss
Description: We will enroll up to 200 weight-loss challenge participants to receive text messages on personal mobile phones throughout the challenge. Consent and enrollment in the trial will take place at registration for the weight-loss community challenge in the language of their choice. Recruited participants will be randomly assigned to a group after consenting to the study and the timing and content of text messages will vary according to group assignment (Groups A - D).~Group A will receive weekly reminders for upcoming weigh-in events. Group B will receive the same weekly reminders but will also receive one-way messages every two weeks providing the participant motivational messages/topics and weight loss health tips. Group C will receive the same text messages as Group B but will also receive weekly prompts to self-monitor weight status. Group D will receive the same text messages as Group C plus daily prompts that will act as a guide for the participant to monitor behavior changes.
Study: NCT02156999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ibandronic acid, vitamin D
Study: NCT03227432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, a corticosteroid, is similar to a natural hormone produced by adrenal glands. It relieves inflammation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide which is an immunomodulatory drug. This means that pomalidomide modulates the immune system to help fight diseases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Elotuzumab is an antibody, that stimulates the immune system to fight diseases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Elotuzumab is an antibody, that stimulates the immune system to fight diseases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab works by blocking an inhibitory signal within immune cells, potentially allowing the immune system to fight the cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab works by blocking an inhibitory signal within immune cells, potentially allowing the immune system to fight the cancer
Study: NCT02809183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC101
Description: oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC101
Description: oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC101
Description: oral suspension
Study: NCT03385096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -8 to -6.~-7 to -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -5 to -4. on days -3 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16)
Description: Etoposide was administered at 10 mg/kg/day on days -3 to -2.~-3 to -2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan was administered at 200mg/m2 on day -2.
Study: NCT03776409

Intervention type: DRUG
Intervention: vancomycin plus piperacillin/tazobactam
Description: Patients in intensive care unit who received the combination of VAN(vancomycin) and PTZ (piperacillin/tazobactam) for at least 48 hours, had a serum creatinine level measured in the 24-hour of hospital admission.The dosage and frequency of VAN and PTZ was adjusted based on clinical practice and patient characteristics.

Intervention type: DRUG
Intervention: vancomycin plus other beta-lactams
Description: Patients in intensive care unit who received the combination of VAN (vancomycin) and other beta-lactams (cefoperazone/sulbactam, meropenem, imipenem/siastatin, ceftriaxone, ceftazidime, et al) for at least 48 hours, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and other beta-lactams were adjusted based on clinical practice and patient characteristics.
Study: NCT00278200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated EBV-infected vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated EBV-infected vaccine
Study: NCT02784925

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound (US) B mode image
Description: Ultrasound (US) B mode image is an alternative method to measure tissue structure~and has proven to be an accurate technique to measure subcutaneous fat thickness.
Study: NCT04921280

Intervention type: BEHAVIORAL
Intervention: Internet based Cognitive Behavioural Therapy
Description: The treatment program consists of 12 chapters or modules spread over 12 weeks and contains written information, different exercises and weekly homework assignment. Patients get access to the CBT program via an internet portal and they have weekly contact with a licenced psychologist via encrypted email. Focus of the therapist support is to review the content of the weekly module, reinforce progress and engagement in therapy and assist with treatment difficulties. If needed, therapist can contact patients via telephone. Patients receive weekly reminders via SMS to login to the portal and fill out self-report measures.
Study: NCT03807323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counselling and exercise
Description: The program consists of:~1. Instructor-led training twice a week,~2. One individual nutritionist counselling session of followed by three group based two-hour nutritionist counselling focusing on practical food purchase and preparation and~3. Three two-hour psychologist-led group counselling sessions based on implementation intentions theory and practical help to make if-then plans focusing on changing food and activity habits.
Study: NCT01285531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compass Lumbar Puncture Enhanced
Description: Participants randomly assigned to this group will receive a lumbar puncture using the Compass device.
Study: NCT05067049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected application arm
Description: patients have to respond different questionnaires about their quality of life on the mobile app.~And follow-up visits with the physicians as usual

Intervention type: DEVICE
Group type: OTHER
Intervention: Unconnected arm
Description: Follow-up visits with the pysicians as usual
Study: NCT02942303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dysport

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dysport

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral orbicularis injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral orbicularis + corrugator injection
Study: NCT01663909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided imagery intervention
Description: A 30-min DVD was developed which included general information on pain management as well as a section on guided imagery using sounds and images.
Study: NCT03276975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TISSEEL
Description: TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (\>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TISSEEL
Description: TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (\>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients
Study: NCT03643419

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laminectomy
Description: According to the standard procedure of laminectomy for acute spinal cord injury

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laminectomy
Description: According to the standard procedure of laminectomy for acute spinal cord injury

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal nerve laser therapeutic apparatus（Composed of 808-band fully automatic control laser device and implantable 360° scattering medical fiber）
Description: According to the standard procedure of decompression of laminectomy for acute spinal cord injury, the patient in the Near Infrared Light Irradiation Group placed the implantable 360° scattering fiber laterally above the operation area at the end of the operation. Near infrared light irradiation is applied by spinal nerve laser therapeutic apparatus every day from the day after surgery, once a day for 60 minutes each time.
Study: NCT01037166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablet, P.O., 0.5 mg or 1mg, once daily, 52 weeks
Study: NCT01661244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV568 single dose
Description: Safety and tolerability of single escalating doses in normal human volunteers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV568 matching placebo single dose
Description: Safety and tolerability of escalating repeat doses in normal human volunteers.
Study: NCT01919879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + Afatinib
Description: Afatinib taken orally, cetuximab administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab + Afatinib
Description: Afatinib taken orally, cetuximab administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab administered intravenously
Study: NCT02319681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple Reminiscence (SR)
Description: SR is a 30-minute psychoeducational activity administered by a trained RA at 4 home visits (week 2, week 3, week 7, and week 19). SR has a didactic component using the SR manual that the couple retains, viewing one of the brief video-vignettes illustrating the application of reminiscence techniques (a different video-vignette will be viewed at each visit), and facilitation of caregiver practice in applying the techniques, using a recent example of anxiety-linked experience of the person with EAD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple Reminiscence (SR)
Description: SR is a 30-minute psychoeducational activity administered by a trained RA at 4 home visits (week 2, week 3, week 7, and week 19). SR has a didactic component using the SR manual that the couple retains, viewing one of the brief video-vignettes illustrating the application of reminiscence techniques (a different video-vignette will be viewed at each visit), and facilitation of caregiver practice in applying the techniques, using a recent example of anxiety-linked experience of the person with EAD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control (AC)
Description: AC is a 30-minute in which the person with EAD, the caregiver and the RA review and discuss the day's newspaper headlines. The RA will use communication techniques specifically designed to keep the conversation present focused at 4 home visits (week 2, week 3, week 7, and week 19).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control (AC)
Description: AC is a 30-minute in which the person with EAD, the caregiver and the RA review and discuss the day's newspaper headlines. The RA will use communication techniques specifically designed to keep the conversation present focused at 4 home visits (week 2, week 3, week 7, and week 19).
Study: NCT03149588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Using propofol and remifentanil as maintenance of general anesthesia during caesarean section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Using sevoflurane and remifentanil as maintenance of general anesthesia during caesarean section.
Study: NCT01412671

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients who have received Nexavar for unresectable or advanced RCC.
Study: NCT00667927

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: See Detailed Description section for description of treatment plan.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: See Detailed Description section for description of treatment plan.

Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: See Detailed Description section for description of treatment plan.
Study: NCT02546713

Intervention type: OTHER
Group type: OTHER
Intervention: Abutment with concave subcritical contour
Description: Implants will be restored with abutments with concave configuration of the subcritical contour

Intervention type: OTHER
Group type: OTHER
Intervention: Abutment with convex subcritical contour
Description: Implants will be restored with abutments with convex configuration of the subcritical contour
Study: NCT01024426

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
Study: NCT00895986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversation Maps Diabetes Education
Description: The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, Inc (Healthy I) and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) Diabetes Overview, 2) Diabetes and Healthy Eating, 3) Blood Glucose and Monitoring, and 4) The Natural Course of Diabetes (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Healthy Living Diabetes Education
Description: The Joslin Clinic offers a series of two 120-minute classes specifically for people with diabetes that address dyslipidemia and blood pressure problems. A registered nurse and/or a registered dietitian teach the classes, which have a formal written curriculum, including PowerPoint slides.
Study: NCT02659761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir/abacavir/lamivudine
Description: 600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine single tablet taken orally, once daily, during 96 weeks
Study: NCT01957657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: faldaprevir
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: faldaprevir
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: faldaprevir
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: faldaprevir
Description: oral administration
Study: NCT00217256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Stenting
Description: Endeavor Drug Eluting Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Stenting
Description: Cypher Drug Eluting Stent